Benny Yang
Chief Scientific Officer Biocytogen
Seminars
Tuesday 24th February 2026
RenBiologics Accelerates the Development of Multi-Specific ADCs
12:30 pm
- Showcasing how Biocytogen provides a unique, fully characterised library of fully human antibody binders targeting over 1,000 druggable proteins
- Unveiling how several bispecific ADC assets, utilising a common light chain and our proprietary Topo1 payload, are now in clinical trials
- Exploring RenNano mice generate fully human nanobodies for next-generation ADC applications
